What targeted therapies are available for Triple-Negative Breast Cancer

Q: What targeted therapies are available for Triple-Negative Breast Cancer

Triple-negative breast cancer TNBC is challenging because the cancer cells lack three important receptors—estrogen receptors ER-, progesterone receptors PR-, and HER2 receptors HER2-—which limits some treatment options. However, there ARE targeted therapies available. Let me explain what's available and how doctors approach this. Since TNBC lacks hormone receptors and HER2, doctors cannot use hormone therapy or HER2-targeted drugs. Instead, they focus on: - Chemotherapy as the backbone of treatm

Triple-Negative Breast CancerMay 20, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Targeted Therapies for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is challenging because the cancer cells lack three important receptors—estrogen receptors (ER-), progesterone receptors (PR-), and HER2 receptors (HER2-)—which limits some treatment options. However, there ARE targeted therapies available. Let me explain what's available and how doctors approach this.

How Doctors Think About TNBC Treatment

Since TNBC lacks hormone receptors and HER2, doctors cannot use hormone therapy or HER2-targeted drugs. Instead, they focus on:

Chemotherapy as the backbone of treatment
Immunotherapy to activate the immune system
PARP inhibitors (if you have specific genetic mutations)
Clinical trials with emerging therapies

Available Targeted Therapy Options

1. Immunotherapy - Pembrolizumab (Keytruda)

What it does: Pembrolizumab is an immune checkpoint inhibitor that "turns on" your immune system to recognize and attack cancer cells.

How it's used: According to NCCN Guidelines, pembrolizumab is combined with chemotherapy for early-stage TNBC:

Preoperative (before surgery): Pembrolizumab + carboplatin + paclitaxel, followed by pembrolizumab + cyclophosphamide with doxorubicin or epirubicin
Adjuvant (after surgery): Continued pembrolizumab treatment

This approach is particularly important because if there is residual disease (cancer remaining) after chemotherapy, pembrolizumab helps prevent recurrence.

2. PARP Inhibitors - Olaparib (Lynparza) or Talazoparib (Talzenna)

What they do: PARP inhibitors block a protein (PARP) that repairs damaged cancer cells. When PARP is blocked, cancer cells can't repair themselves and die.

Who benefits: These are used if you have a germline BRCA1 or BRCA2 mutation (inherited genetic mutation). According to NCCN Guidelines, olaparib is an adjuvant-only option (used after surgery) for TNBC patients with BRCA mutations.

Important: You would need genetic testing to determine if you have a BRCA mutation before this option applies to you.

General Treatment Approach for TNBC

According to NCCN Guidelines, the standard approach typically includes:

Preferred chemotherapy combinations:

Doxorubicin + cyclophosphamide (AC) followed by paclitaxel
Docetaxel + cyclophosphamide (TC)

Often combined with:

Pembrolizumab (immunotherapy) for enhanced immune response

Important Distinctions

What is NOT used for TNBC:

❌ HER2-targeted therapies (trastuzumab, pertuzumab, etc.) — because TNBC is HER2-negative
❌ Hormone therapy/endocrine therapy — because TNBC is ER- and PR-negative
❌ CDK4/6 inhibitors — these are for hormone receptor-positive cancers

Questions to Ask Your Oncologist

Since your specific situation requires your doctor's evaluation, here are important questions:

Do I have a BRCA1 or BRCA2 mutation? (This determines if PARP inhibitors are an option)
Is pembrolizumab recommended as part of my treatment plan? (Especially important for early-stage TNBC)
What is the stage of my cancer, and how does that affect which targeted therapies you recommend?
Are there clinical trials available for TNBC that I should consider?
What side effects should I expect from the immunotherapy or other targeted therapies?

Why This Matters

TNBC research is advancing rapidly. According to NCCN Guidelines, immunotherapy combined with chemotherapy has improved outcomes for TNBC patients compared to chemotherapy alone. Your oncologist will determine the most appropriate approach for YOUR specific case based on: